The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Open accessAbstract
Influenza viruses pose a significant threat to the public and are a burden on global health systems. Each year, influenza vaccines must be rapidly produced to match circulating viruses, a process constrained by dated technology and vulnerable to unexpected strains emerging from humans and animal reservoirs. Here we use knowledge of protein structure to design self-assembling nanoparticles that elicit broader and more potent immunity than traditional influenza vaccines. The viral haemagglutinin was genetically fused to ferritin, a protein that naturally forms nanoparticles composed of 24 identical polypeptides. Haemagglutinin was inserted at the interface of adjacent subunits so that it spontaneously assembled and generated eight trimeric viral spikes on its surface. Immunization with this influenza nanoparticle vaccine elicited haemagglutination inhibition antibody titres more than tenfold higher than those from the licensed inactivated vaccine. Furthermore, it elicited neutralizing antibodies to two highly conserved vulnerable haemagglutinin structures that are targets of universal vaccines: the stem and the receptor binding site on the head. Antibodies elicited by a 1999 haemagglutinin–nanoparticle vaccine neutralized H1N1 viruses from 1934 to 2007 and protected ferrets from an unmatched 2007 H1N1 virus challenge. This structure-based, self-assembling synthetic nanoparticle vaccine improves the potency and breadth of influenza virus immunity, and it provides a foundation for building broader vaccine protection against emerging influenza viruses and other pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationAntibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Self-citationSui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L.-M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1566 · Cited by 1,130
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 822
Magnetoferritin: in Vitro Synthesis of a Novel Magnetic Protein
Meldrum, F. C., Heywood, B. R., & Mann, S. (1992) · Science · doi:10.1126/science.1636086 · Cited by 572
Okuno, Y., Isegawa, Y., Sasao, F., & Ueda, S. (1993) · Journal of Virology · doi:10.1128/jvi.67.5.2552-2558.1993 · Cited by 489
Cross-neutralization of influenza A viruses mediated by a single antibody loop
Ekiert, D. C., Kashyap, A. K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J. H., Dillon, M. A., O’Neil, R. E., Faynboym, A. M., et al. (2012) · Nature · doi:10.1038/nature11414 · Cited by 481
NEUTRALIZING ANTIVIRAL B CELL RESPONSES
Bachmann, M. F., & Zinkernagel, R. M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.235 · Cited by 471
Whittle, J. R. R., Zhang, R., Khurana, S., King, L. R., Manischewitz, J., Golding, H., Dormitzer, P. R., Haynes, B. F., Walter, E. B., Moody, M. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111497108 · Cited by 439
Self-citationCorti, D., Suguitan, A. L., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C., Luke, C. J., Torres-Velez, F. J., Temperton, N. J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41902 · Cited by 437
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Influenza Vaccines for the Future
Lambert, L. C., & Fauci, A. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1002842 · Cited by 389
Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination
Wei, C.-J., Boyington, J. C., McTamney, P. M., Kong, W.-P., Pearce, M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z.-Y., et al. (2010) · Science · doi:10.1126/science.1192517 · Cited by 337
Self-citationThe history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Structural and genetic basis for development of broadly neutralizing influenza antibodies
Lingwood, D., McTamney, P. M., Yassine, H. M., Whittle, J. R. R., Guo, X., Boyington, J. C., Wei, C.-J., & Nabel, G. J. (2012) · Nature · doi:10.1038/nature11371 · Cited by 268
Self-citationImmunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity
Yang, Z.-Y., Wei, C.-J., Kong, W.-P., Wu, L., Xu, L., Smith, D. F., & Nabel, G. J. (2007) · Science · doi:10.1126/science.1135165 · Cited by 253
Self-citationWei, C.-J., Boyington, J. C., Dai, K., Houser, K. V., Pearce, M. B., Kong, W.-P., Yang, Z.-Y., Tumpey, T. M., & Nabel, G. J. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000799 · Cited by 232
Self-citationSalomon, R., & Webster, R. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.029 · Cited by 227
Krause, J. C., Tsibane, T., Tumpey, T. M., Huffman, C. J., Basler, C. F., & Crowe, J. E. (2011) · Journal of Virology · doi:10.1128/jvi.00700-11 · Cited by 204
PCR-based accurate synthesis of long DNA sequences
Xiong, A.-S., Yao, Q.-H., Peng, R.-H., Duan, H., Li, X., Fan, H.-Q., Cheng, Z.-M., & Li, Y. (2006) · Nature Protocols · doi:10.1038/nprot.2006.103 · Cited by 195
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Ledgerwood, J. E., Wei, C.-J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70240-7 · Cited by 188
Self-citationFerritin in the field of nanodevices
Yamashita, I., Iwahori, K., & Kumagai, S. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.03.005 · Cited by 172
Adaptations of nanoscale viruses and other protein cages for medical applications
LEE, L., & WANG, Q. (2006) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.07.009 · Cited by 168
Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine
Nabel, G. J., & Fauci, A. S. (2010) · Nature Medicine · doi:10.1038/nm1210-1389 · Cited by 152
Self-citationWei, C., Xu, L., Kong, W., Shi, W., Canis, K., Stevens, J., Yang, Z., Dell, A., Haslam, S. M., Wilson, I. A., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00187-08 · Cited by 147
Self-citationImmunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines
Kong, W., Huang, Y., Yang, Z., Chakrabarti, B. K., Moodie, Z., & Nabel, G. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12764-12772.2003 · Cited by 93
Self-citationCho, K. J., Shin, H. J., Lee, J.-H., Kim, K.-J., Park, S. S., Lee, Y., Lee, C., Park, S. S., & Kim, K. H. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.04.078 · Cited by 90
Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination
Kong, W., Hood, C. L., Yang, Z., Wei, C., Xu, L., García‐Sastre, A., Tumpey, T. M., & Nabel, G. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607564103 · Cited by 81
Self-citation
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.-Y., Ofek, G., et al. (2014) · Nature · doi:10.1038/nature13808 · Cited by 740
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 699
Self-citation
Metadata
- Authors
- Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J.
- Venue
- Nature
- Published
- 2013-05-22
- Volume
- 499
- Issue
- 7456
- Pages
- 102-106
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2002844537
- Cited by
- 885
- References
- 31
- FWCI
- 31.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.